Skip to main content
icon for FDA approvals in July
Tecnologia·Science

FDA approvals in July

icon for FDA approvals in July
Tecnologia·Science

FDA approvals in July

Ended: lug 31, 2025

apr 30

apr 30

mag 18

Ended: lug 31, 2025

apr 30

apr 30

mag 18

$108,387 Vol.

31 lug 2025
Polymarket

$108,387 Vol.

Polymarket

RP1 (BLA)

$78,750 Vol.

No

Blenrep (BLA)

$13,076 Vol.

No

TransCon hGH (sBLA)

$3,355 Vol.

Yes

Aficamten (NDA)

$8,017 Vol.

No

Empaveli (sNDA)

$852 Vol.

Yes

Sepiapterin (NDA)

$3,598 Vol.

Yes

Odronextamab/Ordspono (Resubmitted BLA)

$739 Vol.

No

This market will resolve to "Yes" if the U.S. Food and Drug Administration (FDA) grants full or conditional approval for the listed drug by July 31, 2025, 11:59 PM ET. Otherwise, this market will resolve to "No." An approval is defined as: For new drugs: FDA issuance of an approval letter for a New Drug Application (NDA) or Biologics License Application (BLA) For already-marketed drugs seeking new indications: FDA approval of a supplemental NDA (sNDA) or supplemental BLA (sBLA) for the specific indication referenced For generic drugs: FDA approval of an Abbreviated New Drug Application (ANDA) For biosimilars: FDA approval of a 351(k) application The following constitute qualifying approvals: Standard approval (traditional approval based on clinical benefit), Accelerated approval (based on surrogate endpoints), Approval with Risk Evaluation and Mitigation Strategy (REMS), Approval with restricted distribution or indication limitations, except compassionate use/expanded access programs The following do not constitute qualifying approvals: Approvable letters that require additional actions before approval Tentative approvals pending patent or exclusivity expiration FDA requests for additional information or studies Extension of Prescription Drug User Fee Amendments dates Approval for compassionate use or expanded access programs only Approval only for export or for use outside the United States Emergency Use Authorization (EUA) without full approval Complete Response Letters (CRLs) indicating the application cannot be approved in its current form This market will immediately resolve to "No" if the FDA issues a Complete Response Letter (CRL) or explicitly declines to approve the application. If the drug sponsor withdraws the application before the end of the month, the market will resolve to "No" immediately. If the listed drug is approved before the end of the month, the market will resolve to "Yes," regardless of potential Advisory Committee votes against approval or later withdrawal of approval. Conditional approvals may include post-marketing requirements or commitments and still qualify. The primary resolution source will be official information from the FDA; however, a consensus of credible reporting will also be used.

This market will resolve to "Yes" if the U.S. Food and Drug Administration (FDA) grants full or conditional approval for the listed drug by July 31, 2025, 11:59 PM ET. Otherwise, this market will resolve to "No."

An approval is defined as:
For new drugs: FDA issuance of an approval letter for a New Drug Application (NDA) or Biologics License Application (BLA)
For already-marketed drugs seeking new indications: FDA approval of a supplemental NDA (sNDA) or supplemental BLA (sBLA) for the specific indication referenced
For generic drugs: FDA approval of an Abbreviated New Drug Application (ANDA)
For biosimilars: FDA approval of a 351(k) application

The following constitute qualifying approvals:
Standard approval (traditional approval based on clinical benefit), Accelerated approval (based on surrogate endpoints), Approval with Risk Evaluation and Mitigation Strategy (REMS), Approval with restricted distribution or indication limitations, except compassionate
use/expanded access programs

The following do not constitute qualifying approvals:
Approvable letters that require additional actions before approval
Tentative approvals pending patent or exclusivity expiration
FDA requests for additional information or studies
Extension of Prescription Drug User Fee Amendments dates
Approval for compassionate use or expanded access programs only
Approval only for export or for use outside the United States
Emergency Use Authorization (EUA) without full approval
Complete Response Letters (CRLs) indicating the application cannot be approved in its current form

This market will immediately resolve to "No" if the FDA issues a Complete Response Letter (CRL) or explicitly declines to approve the application. If the drug sponsor withdraws the application before the end of the month, the market will resolve to "No" immediately.

If the listed drug is approved before the end of the month, the market will resolve to "Yes," regardless of potential Advisory Committee votes against approval or later withdrawal of approval.

Conditional approvals may include post-marketing requirements or commitments and still qualify.

The primary resolution source will be official information from the FDA; however, a consensus of credible reporting will also be used.
Volume
$108,387
Data di fine
31 lug 2025
Mercato aperto
Jul 21, 2025, 7:40 PM ET

Resolver

0x157Ce2d67...
This market will resolve to "Yes" if the U.S. Food and Drug Administration (FDA) grants full or conditional approval for the listed drug by July 31, 2025, 11:59 PM ET. Otherwise, this market will resolve to "No." An approval is defined as: For new drugs: FDA issuance of an approval letter for a New Drug Application (NDA) or Biologics License Application (BLA) For already-marketed drugs seeking new indications: FDA approval of a supplemental NDA (sNDA) or supplemental BLA (sBLA) for the specific indication referenced For generic drugs: FDA approval of an Abbreviated New Drug Application (ANDA) For biosimilars: FDA approval of a 351(k) application The following constitute qualifying approvals: Standard approval (traditional approval based on clinical benefit), Accelerated approval (based on surrogate endpoints), Approval with Risk Evaluation and Mitigation Strategy (REMS), Approval with restricted distribution or indication limitations, except compassionate use/expanded access programs The following do not constitute qualifying approvals: Approvable letters that require additional actions before approval Tentative approvals pending patent or exclusivity expiration FDA requests for additional information or studies Extension of Prescription Drug User Fee Amendments dates Approval for compassionate use or expanded access programs only Approval only for export or for use outside the United States Emergency Use Authorization (EUA) without full approval Complete Response Letters (CRLs) indicating the application cannot be approved in its current form This market will immediately resolve to "No" if the FDA issues a Complete Response Letter (CRL) or explicitly declines to approve the application. If the drug sponsor withdraws the application before the end of the month, the market will resolve to "No" immediately. If the listed drug is approved before the end of the month, the market will resolve to "Yes," regardless of potential Advisory Committee votes against approval or later withdrawal of approval. Conditional approvals may include post-marketing requirements or commitments and still qualify. The primary resolution source will be official information from the FDA; however, a consensus of credible reporting will also be used.

Esito proposto: No

Nessuna contestazione

Esito finale: No

This market will resolve to "Yes" if the U.S. Food and Drug Administration (FDA) grants full or conditional approval for the listed drug by July 31, 2025, 11:59 PM ET. Otherwise, this market will resolve to "No." An approval is defined as: For new drugs: FDA issuance of an approval letter for a New Drug Application (NDA) or Biologics License Application (BLA) For already-marketed drugs seeking new indications: FDA approval of a supplemental NDA (sNDA) or supplemental BLA (sBLA) for the specific indication referenced For generic drugs: FDA approval of an Abbreviated New Drug Application (ANDA) For biosimilars: FDA approval of a 351(k) application The following constitute qualifying approvals: Standard approval (traditional approval based on clinical benefit), Accelerated approval (based on surrogate endpoints), Approval with Risk Evaluation and Mitigation Strategy (REMS), Approval with restricted distribution or indication limitations, except compassionate use/expanded access programs The following do not constitute qualifying approvals: Approvable letters that require additional actions before approval Tentative approvals pending patent or exclusivity expiration FDA requests for additional information or studies Extension of Prescription Drug User Fee Amendments dates Approval for compassionate use or expanded access programs only Approval only for export or for use outside the United States Emergency Use Authorization (EUA) without full approval Complete Response Letters (CRLs) indicating the application cannot be approved in its current form This market will immediately resolve to "No" if the FDA issues a Complete Response Letter (CRL) or explicitly declines to approve the application. If the drug sponsor withdraws the application before the end of the month, the market will resolve to "No" immediately. If the listed drug is approved before the end of the month, the market will resolve to "Yes," regardless of potential Advisory Committee votes against approval or later withdrawal of approval. Conditional approvals may include post-marketing requirements or commitments and still qualify. The primary resolution source will be official information from the FDA; however, a consensus of credible reporting will also be used.

This market will resolve to "Yes" if the U.S. Food and Drug Administration (FDA) grants full or conditional approval for the listed drug by July 31, 2025, 11:59 PM ET. Otherwise, this market will resolve to "No."

An approval is defined as:
For new drugs: FDA issuance of an approval letter for a New Drug Application (NDA) or Biologics License Application (BLA)
For already-marketed drugs seeking new indications: FDA approval of a supplemental NDA (sNDA) or supplemental BLA (sBLA) for the specific indication referenced
For generic drugs: FDA approval of an Abbreviated New Drug Application (ANDA)
For biosimilars: FDA approval of a 351(k) application

The following constitute qualifying approvals:
Standard approval (traditional approval based on clinical benefit), Accelerated approval (based on surrogate endpoints), Approval with Risk Evaluation and Mitigation Strategy (REMS), Approval with restricted distribution or indication limitations, except compassionate
use/expanded access programs

The following do not constitute qualifying approvals:
Approvable letters that require additional actions before approval
Tentative approvals pending patent or exclusivity expiration
FDA requests for additional information or studies
Extension of Prescription Drug User Fee Amendments dates
Approval for compassionate use or expanded access programs only
Approval only for export or for use outside the United States
Emergency Use Authorization (EUA) without full approval
Complete Response Letters (CRLs) indicating the application cannot be approved in its current form

This market will immediately resolve to "No" if the FDA issues a Complete Response Letter (CRL) or explicitly declines to approve the application. If the drug sponsor withdraws the application before the end of the month, the market will resolve to "No" immediately.

If the listed drug is approved before the end of the month, the market will resolve to "Yes," regardless of potential Advisory Committee votes against approval or later withdrawal of approval.

Conditional approvals may include post-marketing requirements or commitments and still qualify.

The primary resolution source will be official information from the FDA; however, a consensus of credible reporting will also be used.
Volume
$108,387
Data di fine
31 lug 2025
Mercato aperto
Jul 21, 2025, 7:40 PM ET

Resolver

0x157Ce2d67...
This market will resolve to "Yes" if the U.S. Food and Drug Administration (FDA) grants full or conditional approval for the listed drug by July 31, 2025, 11:59 PM ET. Otherwise, this market will resolve to "No." An approval is defined as: For new drugs: FDA issuance of an approval letter for a New Drug Application (NDA) or Biologics License Application (BLA) For already-marketed drugs seeking new indications: FDA approval of a supplemental NDA (sNDA) or supplemental BLA (sBLA) for the specific indication referenced For generic drugs: FDA approval of an Abbreviated New Drug Application (ANDA) For biosimilars: FDA approval of a 351(k) application The following constitute qualifying approvals: Standard approval (traditional approval based on clinical benefit), Accelerated approval (based on surrogate endpoints), Approval with Risk Evaluation and Mitigation Strategy (REMS), Approval with restricted distribution or indication limitations, except compassionate use/expanded access programs The following do not constitute qualifying approvals: Approvable letters that require additional actions before approval Tentative approvals pending patent or exclusivity expiration FDA requests for additional information or studies Extension of Prescription Drug User Fee Amendments dates Approval for compassionate use or expanded access programs only Approval only for export or for use outside the United States Emergency Use Authorization (EUA) without full approval Complete Response Letters (CRLs) indicating the application cannot be approved in its current form This market will immediately resolve to "No" if the FDA issues a Complete Response Letter (CRL) or explicitly declines to approve the application. If the drug sponsor withdraws the application before the end of the month, the market will resolve to "No" immediately. If the listed drug is approved before the end of the month, the market will resolve to "Yes," regardless of potential Advisory Committee votes against approval or later withdrawal of approval. Conditional approvals may include post-marketing requirements or commitments and still qualify. The primary resolution source will be official information from the FDA; however, a consensus of credible reporting will also be used.

Esito proposto: No

Nessuna contestazione

Esito finale: No

Fai attenzione ai link esterni.

Domande frequenti

"FDA approvals in July" è un mercato predittivo su Polymarket con 7 possibili esiti dove i trader comprano e vendono azioni in base a ciò che credono accadrà. L'esito attualmente in testa è "TransCon hGH (sBLA)" a 100%, seguito da "Empaveli (sNDA)" a 100%. I prezzi riflettono probabilità aggregate in tempo reale. Ad esempio, un'azione quotata a 100¢ implica che il mercato assegna collettivamente una probabilità di 100% a quell'esito. Queste quote cambiano continuamente man mano che i trader reagiscono a nuovi sviluppi e informazioni. Le azioni nell'esito corretto possono essere riscattate per $1 ciascuna alla risoluzione del mercato.

Ad oggi, "FDA approvals in July" ha generato $108.4K in volume totale di trading dal lancio del mercato il Jul 21, 2025. Questo livello di attività di trading riflette un forte coinvolgimento della comunità Polymarket e contribuisce a garantire che le quote attuali siano informate da un ampio pool di partecipanti al mercato. Puoi seguire i movimenti di prezzo in tempo reale e fare trading su qualsiasi esito direttamente su questa pagina.

Per fare trading su "FDA approvals in July", esplora i 7 esiti disponibili elencati in questa pagina. Ogni esito mostra un prezzo corrente che rappresenta la probabilità implicita del mercato. Per prendere una posizione, seleziona l'esito che ritieni più probabile, scegli "Sì" per fare trading a suo favore o "No" per fare trading contro di esso, inserisci il tuo importo e clicca "Trading". Se il tuo esito scelto è corretto alla risoluzione del mercato, le tue azioni "Sì" pagano $1 ciascuna. Se è errato, pagano $0. Puoi anche vendere le tue azioni in qualsiasi momento prima della risoluzione se vuoi consolidare un profitto o limitare una perdita.

L'attuale favorito per "FDA approvals in July" è "TransCon hGH (sBLA)" a 100%, il che significa che il mercato assegna una probabilità di 100% a quell'esito. L'esito successivo più vicino è "Empaveli (sNDA)" a 100%. Queste quote si aggiornano in tempo reale man mano che i trader comprano e vendono azioni, quindi riflettono l'ultima visione collettiva di ciò che è più probabile che accada. Controlla frequentemente o aggiungi questa pagina ai preferiti per seguire come cambiano le quote man mano che emergono nuove informazioni.

Le regole di risoluzione per "FDA approvals in July" definiscono esattamente cosa deve accadere affinché ogni esito venga dichiarato vincitore — comprese le fonti di dati ufficiali utilizzate per determinare il risultato. Puoi consultare i criteri completi di risoluzione nella sezione "Regole" di questa pagina sopra i commenti. Ti consigliamo di leggere attentamente le regole prima di fare trading, poiché specificano le condizioni precise, i casi limite e le fonti che regolano come viene risolto questo mercato.